Disease · MONDO_0005146
post-traumatic stress disorder
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. post-traumatic stress disorder. Diseases, record MONDO_0005146. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005146
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
ACUTE POST TRAUMATIC STRESS DIS, Acute Post Traumatic Stress Disorder, CHRONIC POST TRAUMATIC STRESS DIS, Chronic Post Traumatic Stress Disorder, DELAYED ONSET POST TRAUMATIC STRESS DIS, Delayed Onset Post Traumatic Stress Disorder, Neuroses, Post Traumatic, Neuroses, Posttraumatic, POST TRAUMATIC STRESS DIS, POSTTRAUMATIC STRESS DIS, POSTTRAUMATIC STRESS DISORDERS, PTSD, PTSD - Post-traumatic stress disorder, Post Traumatic Stress Disorders, Post-Traumatic Neuroses, Post-Traumatic Neurosis, Post-traumatic stress syndrome, Posttraumatic Neuroses, Posttraumatic stress disorder, Posttraumatic stress disorder (disorder), Posttraumatic stress disorder, NOS, STRESS DIS POST TRAUMATIC, STRESS DIS POSTTRAUMATIC, Stress Disorder, Post Traumatic, Stress Disorder, Posttraumatic, Stress Disorders, Post Traumatic, Stress Disorders, Posttraumatic, disorder, post-traumatic stress, post-traumatic stress disease, traumatic neurosis
- Open Targets
Drugs139
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PAROXETINE HYDROCHLORIDE | CHEMBL6067650 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| SERTRALINE HYDROCHLORIDE | CHEMBL1709 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| PAROXETINE MESYLATE | CHEMBL1200609 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| MIDOMAFETAMINE | CHEMBL43048 | Small molecule | Phase 3 | ClinicalTrials.gov | 44 | 44 | 43 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 22 | 22 | 22 | Drugs and targets |
| PSILOCYBIN | CHEMBL194378 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| PROPRANOLOL | CHEMBL27 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| PAROXETINE | CHEMBL490 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| PRAZOSIN | CHEMBL2 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
1 to 10 of 139
See all 139 drugsTargets123
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Sodium-dependent serotonin transporter | 17 | Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent | Approval | https://conductscience.org/library/genes/6532 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 13 | Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 9 | Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 8 | D2-like dopamine receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 8 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 8 | Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
1 to 10 of 123
See all 123 targetsTrials329
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 14 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03466346 | SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project | Not applicable | 2,162 | 2025-12-02 | Depression, Unipolar, Posttraumatic Stress Disorder, Trauma | FLUOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | Not applicable | 635 | 2021-07-02 | Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease | CITALOPRAM, DIPHENHYDRAMINE, DULOXETINE, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, PRAZOSIN, SERTRALINE, TRAZODONE, VENLAFAXINE | Its record names the disease | ClinicalTrials.gov |
| NCT04174170 | Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder | Phase 3 | 591 | 2025-05-30 | Post Traumatic Stress Disorder | BREXPIPRAZOLE, SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT04124614 | Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Phase 3 | 450 | 2025-06-13 | Post Traumatic Stress Disorder | BREXPIPRAZOLE, SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT01987960 | Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD) | Phase 3 | 417 | 2017-03-13 | Post-traumatic Stress Disorder, PTSD | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03062540 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | Phase 3 | 358 | 2024-05-22 | PTSD | CYCLOBENZAPRINE | Its record names the disease | ClinicalTrials.gov |
| NCT03033069 | A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD) | Phase 2 | 336 | 2021-12-08 | Stress Disorders, Post-Traumatic | BREXPIPRAZOLE, SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT00532493 | Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD | Phase 3 | 304 | 2014-06-18 | PTSD, Sleep Disorders | PRAZOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT00099983 | Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder | Phase 2 | 296 | 2014-08-22 | Stress Disorders, Post-Traumatic | RISPERIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT02277704 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | Phase 2 | 245 | 2024-06-20 | PTSD | CYCLOBENZAPRINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 329
See all 329 trialsComparisons in its trials156
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Brexpiprazole + Sertraline vs Sertraline + Placebo: deaths from any cause | 0 of 205 | 1 of 196 | 401 | NCT04124614 | Trial comparisons |
| Brexpiprazole + Sertraline vs Sertraline + Placebo: serious adverse events | 1 of 205 | 4 of 196 | 401 | NCT04124614 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause | 0 of 179 | 0 of 179 | 358 | NCT03062540 | Trial comparisons |
| TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events | 3 of 175 | 5 of 176 | 351 | NCT03062540 | Trial comparisons |
| Prazosin Group vs Placebo Group: serious adverse events | 18 of 152 | 17 of 152 | 304 | NCT00532493 | Trial comparisons |
| Risperidone vs Sugar Pill: serious adverse events | 16 of 133 | 10 of 134 | 267 | NCT00099983 | Trial comparisons |
| BNC210 900 mg vs Placebo: deaths from any cause | 0 of 105 | 0 of 104 | 209 | NCT04951076 | Trial comparisons |
| BNC210 900 mg vs Placebo: serious adverse events | 0 of 105 | 2 of 104 | 209 | NCT04951076 | Trial comparisons |
1 to 10 of 156
See all 156 comparisons in its trialsPapers from its trials196
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005146
GET https://conductscience.org/api/diseases/v1/MONDO_0005146/drugs?page=2